

Contents

	Historical aspects of Niemann-Pick disease	12
	Biochemistry of Niemann-Pick disease	18
2.1.	Introduction and definitions	18
2.2.	Missing or pathological products of "Niemann-Pick genes"	19
2.3.	Biochemical foundations of diagnosing Niemann-Pick diseases	19
2.3.1.	Niemann-Pick disease, SMPD1-associated	19
2.3.2.	Niemann-Pick disease, transport protein deficiency-associated (NPC1, NPC2)	19
2.3.3.	Chitotriosidase activity in plasma	20
2.3.4.	Determination of oxysterols	20
2.3.5.	Determination of lyso-sphingomyelin-509 (lyso-SM-509)	21
2.3.6.	Determination of bile acids	21
2.4.	Biochemistry of Niemann-Pick diseases that is pathogenetically relevant or suspected to be significant	21
2.4.1.	Niemann-Pick disease, SMPD1-associated	21
2.4.2.	Niemann-Pick disease, transport protein deficiency-associated (NPC1, NPC2) in general	22
2.4.3.	Niemann-Pick disease, transport protein deficiency-associated (NPC1, NPC2), central nervous system	24
2.5.	Animal models	25
2.5.1.	Niemann-Pick disease, SMPD1-associated	25
2.5.2.	Niemann-Pick disease, transport protein deficiency-associated (NPC1, NPC2)	25
2.6.	Therapeutic concepts for the possible influence of pathogenetically significant metabolic changes	26
2.6.1.	Niemann-Pick disease, SMPD1-associated	26
2.6.2.	Niemann-Pick disease, transport protein deficiency-associated (NPC1)	26
	Genetics of Niemann-Pick disease	34
3.1.	Niemann-Pick disease type A/B (NPA/B) [MIM: 257200/607616]	34
3.1.1.	<i>SMPD1</i> gene and ASM protein [HGNC Gene-ID: 11120]	34
3.1.2.	<i>SMPD1</i> variants	34
3.2.	Niemann-Pick disease type C (NPC) [MIM: 257220/607625]	35
3.2.1.	<i>NPC1</i> gene and protein [HGNC Gene-ID: 7897]	36
3.2.2.	<i>NPC1</i> variants	37
3.2.3.	<i>NPC2</i> gene and protein [HGNC Gene-ID: 14537]	38
3.2.4.	<i>NPC2</i> variants	38
3.3.	Challenges of genetic testing in Niemann-Pick disease and outlook	38
3.4.	Genetic databases for Niemann-Pick diseases	39
	Diagnosis of Niemann-Pick disease type C (NPC)	44
4.1.	Recommendations for differential diagnosis and initial diagnosis	44
4.2.	Clinical diagnosis and key findings in NPC	46
4.2.1.	Neuropsychological diagnosis and key findings	46
4.2.2.	Laboratory diagnostics and biomarkers	47

4.3.	Significance of genetic testing in NPC	50
4.3.1.	Next-generation sequencing (NGS) and gene panels	52
4.3.2.	Differentiation from acid sphingomyelinase deficiency (ASMD)	52
4.4.	Differential diagnosis of similar lysosomal diseases.....	54
	Clinical manifestation	58
5.1.	Niemann-Pick disease type A and type B.....	58
5.2.	Niemann-Pick type C disease	62
5.2.1.	Perinatal type	63
5.2.2.	Infantile type.....	64
5.2.3.	Late-infantile type.....	64
5.2.4.	Juvenile classic type	67
5.2.5.	Adult type	70
5.2.6.	Psychiatric manifestations in Niemann-Pick type C disease.....	71
	Management and treatment of Niemann-Pick diseases	80
6.1.	Management and treatment of Niemann-Pick type A/B disease	80
6.1.1.	Supportive care	80
6.1.2.	Causal therapeutic approaches	81
6.1.3.	Future therapy options	82
6.2.	Management and treatment of Niemann-Pick type C disease.....	83
6.2.1.	Miglustat.....	84
6.2.2.	Bone marrow and liver transplantations.....	85
6.2.3.	Treatment of extrapyramidal symptoms, spasticity, cataplexy and epilepsy.....	85
6.2.4.	Substances in preclinical and experimental studies	86
	Index	87